London-based medtech Lindus Health has announced a new rake of clinical trials which will be managed through its platform. It claims that using its clinical trial management platform it can speed trials up to three times faster than the traditional industry methods.
Lindus Health will work with global healthcare company Pharmanovia to evaluate the safety and efficacy of a treatment for patients with severe insomnia in a real-world setting, with Oto to run a trial for 200 people, evaluating their digital tinnitus solution against in-person therapy and also Dopavision to trial the MyopiaX treatment for children affected by progressive short sightedness - the aim in this particular trial is to increase dopamine levels in the retina to slow the progression of the condition.
“Clinical trials are the biggest bottleneck to improving human health. We’re working with high-growth companies developing the next wave of breakthrough treatments to accelerate the clinical trials process," says co-founder of Lindus Health, Michael Young. “It’s fantastic to be working with the Government and industry pioneers to revolutionise clinical trials to deliver treatments to benefit patients more quickly."
“From monitoring trial data in real time to using machine learning to predict trial outcomes and make improvements to trial designs in advance, we want to simplify and accelerate the trials process and put patients first.”
To date, Lindus Health has raised $6 million in funding - investors include Firstminute, Seedcamp and Peter Thiel (PayPal co-founder). It also received an Innovate UK Smart Grant, part of UK Research and Innovation, worth almost £500,000.